1.
Am J Hematol
; 96(8): E285-E288, 2021 08 01.
Article
in English
| MEDLINE | ID: covidwho-1384099
Subject(s)
COVID-19/epidemiology , Pandemics , SARS-CoV-2 , beta-Thalassemia/epidemiology , Activin Receptors, Type II/therapeutic use , Adult , Asymptomatic Infections , COVID-19/complications , Cardiovascular Diseases/etiology , Chelation Therapy/adverse effects , Clinical Trials as Topic , Comorbidity , Dietary Supplements , Female , Hospitalization/statistics & numerical data , Humans , Immunocompromised Host , Immunoglobulin Fc Fragments/therapeutic use , Iron Chelating Agents/adverse effects , Iron Chelating Agents/therapeutic use , Iron Overload/epidemiology , Iron Overload/etiology , Lebanon/epidemiology , Male , Obesity/epidemiology , Phosphodiesterase Inhibitors/therapeutic use , Prevalence , Recombinant Fusion Proteins/therapeutic use , Severity of Illness Index , Splenectomy , Tertiary Care Centers , Vitamins , beta-Thalassemia/complications , beta-Thalassemia/drug therapy , beta-Thalassemia/immunology
2.
Hematology
; 26(1): 432-434, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1270723
Subject(s)
Blood Transfusion/statistics & numerical data , COVID-19/epidemiology , SARS-CoV-2 , beta-Thalassemia/epidemiology , Afghanistan/epidemiology , Blood Donors/supply & distribution , COVID-19/economics , COVID-19/prevention & control , Comorbidity , Culturally Competent Care , Deferoxamine/supply & distribution , Deferoxamine/therapeutic use , Female , Health Services/supply & distribution , Health Services Needs and Demand , Humans , Literacy , Male , Secondary Prevention , Social Determinants of Health , Transfusion Reaction/prevention & control , Unemployment , beta-Thalassemia/drug therapy , beta-Thalassemia/economics , beta-Thalassemia/therapy
3.
Hemoglobin
; 44(3): 218-220, 2020 May.
Article
in English
| MEDLINE | ID: covidwho-609501
ABSTRACT
We here report the successful recovery from coronavirus disease-19 (COVID-19) pneumonia in a patient with ß-thalassemia major (ß-TM) and severe pulmonary arterial hypertension (PAH), focusing on the patient's comorbidities, therapeutic course and drug interaction.